MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC)
PublisherJohn Wiley and Sons Inc.
MetadataShow full item record
AbstractBackground: The development of biomarkers for the early detection of non-small cell lung cancer (NSCLC) is clinically important. We have developed miRNA biomarkers in sputum and plasma, respectively, for NSCLC. Herein, we evaluate whether integrated analysis of the miRNAs across the different types of specimens could improve the early detection of NSCLC. Methods: Using reverse transcription PCR, we determined expressions of two miRNAs (miRs-31-5p and 210-3p) in sputum and three miRNAs (miRs-21-5p, 210-3p, and 486-5p) in plasma of a training cohort of 76 NSCLC patients and 72 cancer-free smokers. The results were validated in a testing cohort of 56 NSCLC patients and 55 cancer-free smokers. Results: The panels of two sputum miRNAs and three plasma miRNAs had 65.8-75.0% sensitivities and 83.3-87.5% specificities for diagnosis of NSCLC in the training cohort. The individual sputum or plasma miRNA panel had a higher sensitivity for squamous cell carcinoma or adenocarcinoma of the lung, respectively. From the miRNAs, we optimized an integrated panel of biomarkers consisting of two sputum miRNAs (miRs-31-5p and 210-3p) and one plasma miRNA (miR-21-5p) that had higher sensitivity (85.5%) and specificity (91.7%) for diagnosis of NSCLC compared with the individual panels alone. Furthermore, the performance of the integrated panel of biomarkers was independent of histology and stage of NSCLC, and patients' age, sex, and ethnicity. The performance of the integrated panel of biomarkers was confirmed in the testing cohort. Conclusions: Integrating biomarkers across different body fluids would synergistically improve the early detection of NSCLC. Key points: Lung cancer is a heterogeneous disease and develops from complex aberrations. Integrating sputum and plasma miRNAs has higher accuracy than when they are used alone. Copyright 2020 The Authors.
SponsorsThis research was supported by an NSF grant (CBET-1705538).
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85078680139&doi=10.1111%2f1759-7714.13337&partnerID=40&md5=a88087ecc82982722920ab6c13ed7ede; http://hdl.handle.net/10713/11700
- Integrating DNA methylation and microRNA biomarkers in sputum for lung cancer detection.
- Authors: Su Y, Fang H, Jiang F
- Issue date: 2016
- Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers.
- Authors: Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, Fang H, Zhang J, Katz RL, Jiang F
- Issue date: 2010 Dec 15
- Clinical evaluation of microRNA expression profiling in non small cell lung cancer.
- Authors: Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E
- Issue date: 2013 Sep
- Sputum long non-coding RNA biomarkers for diagnosis of lung cancer.
- Authors: Gupta C, Su J, Zhan M, Stass SA, Jiang F
- Issue date: 2019
- miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
- Authors: Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ
- Issue date: 2011 Mar